Incorporating Updated Guidelines into the Management of Breast Cancer: Case Studies and Best Practices - Online

Registration is complimentary.  No pre-registration required.

Thursday, August 1, 2019, 12:00 AM - Sunday, July 31, 2022, 11:00 PM

Dr. Russell is a member of the American College of Physicians, the American Society of Clinical Oncology, the European Society of Medical Oncology, and the American Society of Breast Surgeons. Dr Russell served on the American Cancer Society Cancer Action Network National Board of Directors, and served as the Chairman of the Board. She was a member of the American Cancer Society, Inc. National Board of Directors and chaired the National Reach to Recovery advisory group. She served as a Director on the board of the California Division of the American Cancer Society and was President of the board. She currently is an Honorary Life Member of the California Division of the American Cancer Society. She served as the Chief of staff at USC/Norris Cancer center. She was the Director of the USC/Norris Breast Cancer Center, the director of utilization review at USC/Norris Cancer Center and Co-Chair of the USC Comprehensive Cancer Center Data Safety Monitoring Board

A knowledge activity for Sharp-affiliated or community physicians, pharmacists, nurses, and allied health professionals

1. Articulate the importance of clinical staging and the resources used for comprehensive staging
2. Summarize the importance of timely clinical staging, pathological staging, and prognostic staging and its effect on treatment decisions
3. Describe the significance of biomarkers in breast cancer diagnoses and their utility in treatment decisions
4. List the benefits of reflex testing in breast cancer
5. Describe the factors used in breast cancer risk stratification
6. Describe the role age plays in ensuring a comprehensive breast cancer work-up prior to treatment initiation
7. Identify the role hereditary cancer mutations play in breast cancer treatment decisions
8. List the staging considerations for patients undergoing neo-adjuvant treatment
9. Identify how pregnancy effects biomarker testing and treatment decisions
10. Describe the approach to clinical staging for unexpected breast cancer malignancies

Accreditation:  Sharp HealthCare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit:  Sharp HealthCare designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation:  Sharp HealthCare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CPE Credit:  Sharp HealthCare designates this home study for a maximum of 2.0 contact hours (.20 CEUs).  Partial credit will not be awarded.  Pharmacists can verify their credits at  CPE Monitor within 30 days of completion of this activity.  UAN: 0571-0000-19-034-H01-P

Activity Type:  Knowledge

Nurse Credit:  The California Board of Registered Nursing recognizes the use of Category 1 Continuing Medical Education credit toward credit contact hours.  Report "ACCME Category 1 Credit" as BRN number.  No BRN slip will be given.  Participants must attend the entire conference to receive continuing education credits.

 

       

Disclosure: As an organization accredited by the ACCME, Sharp HealthCare requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.  The ACPE defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months.”  

Sharp HealthCare, encourages faculty to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Cultural & Linguistic Competency: This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency.  The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development.  Cultural and linguistic competency was incorporated into the planning of this activity.

Pharmacists - To Earn Credit:

1. Complete pretest
2. Review module content
3. Pass post test with minimum score of 80%
4. Complete post module evaluation